• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Saluck Randy S. was granted 60,000 shares, increasing direct ownership by 42,857% to 60,140 units

    10/28/21 4:08:28 PM ET
    $STAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STAB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    SALUCK RANDY S.

    (Last) (First) (Middle)
    2537 RESEARCH BOULEVARD, SUITE 201

    (Street)
    FORT COLLINS CO 80526

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Statera Biopharma, Inc. [ STAB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/09/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.005 per share 09/09/2021 A 60,000(1) A $0 60,140(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These securities are restricted stock units (RSUs) that were granted pursuant to the Cleveland Biolabs, Inc. Equity Incentive Plan. The RSUs will be settled solely with Issuer Common Stock and vest in equal monthly portions over the period of 36 months from the grant date, provided that the Reporting Person continues to provide services to the Issuer through each vesting date.
    2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Issuer Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
    /s/ Peter Aronstam, Attorney-in-fact for Randy S. Saluck 10/28/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Chandrasekhar Satishchandran

      3 - Statera Biopharma, Inc. (0001318641) (Issuer)

      3/21/22 7:27:04 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Saluck Randy S. was granted 60,000 shares, increasing direct ownership by 42,857% to 60,140 units

      4 - Statera Biopharma, Inc. (0001318641) (Issuer)

      10/28/21 4:08:28 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Financials

    Live finance-specific insights

    See more
    • Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

      Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

      2/12/25 8:30:00 AM ET
      $STAB
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Statera Biopharma, Inc. Files Form 12b-25

      FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company has filed a Form 12b-25 with the U.S. Securities and Exchange Commission to extend until April 15, 2022 the due date for filing the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in t

      3/31/22 4:05:00 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

      Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021. Conference Call & Webcast Details DateThursday, March 31, 2022Time5:30 p.m. ETLive Audio Webcasthttps://edge.media-server.com/mmc/p/yffrdzzpTeleph

      3/28/22 7:30:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

      Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

      2/12/25 8:30:00 AM ET
      $STAB
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA

      WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ --   Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon

      4/11/24 10:00:00 AM ET
      $FUBO
      $HOUR
      $HTCR
      $MOBQ
      Movies/Entertainment
      Consumer Discretionary
      Catalog/Specialty Distribution
      EDP Services
    • Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

      FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the "Proposed Transaction"). "We believe the proposed merger could e

      3/15/23 8:00:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Statera Biopharma Inc.

      DEFR14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/28/23 9:06:58 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Statera Biopharma Inc.

      DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/27/23 6:01:46 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Statera Biopharma Inc.

      PRE 14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/15/23 9:08:28 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

      FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company's independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders' equity and income, and cash flows for the period ended December 31, 2021. About Statera BiopharmaStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company develo

      6/14/22 7:30:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care